Stifel Reiterates Buy Rating on Jasper Therapeutics (JSPR)
Tweet Send to a Friend
Stifel analyst Ben Burnett reiterated a Buy rating and $80.00 price target on Jasper Therapeutics (NASDAQ: JSPR).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
